Allergy Therapeutics Plc (LON:AGY) is the topic of conversation with Dr Gary Waanders Director of Healthcare Research at Zeus Capital. Since Allergy Therapeutics announced today that it has obtained approval to begin a phase I clinical trial of its Acarovac MPL vaccine in Spain, Gary explains what the product designed to do, what CTA clearance means for the product’s development and on the basis of a fully approved vaccine the sort of sales he thinks might be possible.
Allergy Therapeutics plc is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease. The Company sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities. The Company employs c.495 employees and is listed on the London Stock Exchange.